# Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence

> **NCT01157377** · PHASE2 · COMPLETED · sponsor: **Allergan** · enrollment: 160 (actual)

## Conditions studied

- Urinary Bladder, Overactive

## Interventions

- **DRUG:** AGN-214868
- **DRUG:** AGN-214868 placebo

## Key facts

- **NCT ID:** NCT01157377
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2013-02
- **Final completion:** 2013-05
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2014-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01157377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01157377, "Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence". Retrieved via AI Analytics 2026-06-21 from https://api.ai-analytics.org/clinical/NCT01157377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*